Actinium Pharmaceuticals Inc (ATNM)
7.85
+0.15
(+1.95%)
USD |
NYAM |
May 01, 10:22
Actinium Pharmaceuticals Free Cash Flow: -47.49M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -47.49M |
| September 30, 2023 | -47.79M |
| June 30, 2023 | -42.42M |
| March 31, 2023 | -1.087M |
| December 31, 2022 | 8.278M |
| September 30, 2022 | 11.02M |
| June 30, 2022 | 11.15M |
| March 31, 2022 | -21.14M |
| December 31, 2021 | -21.00M |
| September 30, 2021 | -22.45M |
| June 30, 2021 | -21.80M |
| March 31, 2021 | -21.66M |
| December 31, 2020 | -21.87M |
| September 30, 2020 | -20.38M |
| June 30, 2020 | -20.98M |
| March 31, 2020 | -21.84M |
| December 31, 2019 | -21.53M |
| September 30, 2019 | -20.81M |
| June 30, 2019 | -21.88M |
| March 31, 2019 | -20.74M |
| December 31, 2018 | -20.67M |
| September 30, 2018 | -19.54M |
| June 30, 2018 | -18.74M |
| March 31, 2018 | -21.66M |
| December 31, 2017 | -21.58M |
| Date | Value |
|---|---|
| September 30, 2017 | -22.67M |
| June 30, 2017 | -22.36M |
| March 31, 2017 | -21.45M |
| December 31, 2016 | -20.85M |
| September 30, 2016 | -20.58M |
| June 30, 2016 | -18.53M |
| March 31, 2016 | -17.56M |
| December 31, 2015 | -18.59M |
| September 30, 2015 | -19.65M |
| June 30, 2015 | -20.39M |
| March 31, 2015 | -17.82M |
| December 31, 2014 | -14.50M |
| September 30, 2014 | -10.81M |
| June 30, 2014 | -8.171M |
| March 31, 2014 | -6.488M |
| December 31, 2013 | -6.309M |
| September 30, 2013 | -6.374M |
| June 30, 2013 | -6.681M |
| March 31, 2013 | -6.579M |
| December 31, 2012 | -5.215M |
| September 30, 2012 | -4.318M |
| June 30, 2012 | -2.385M |
| March 31, 2012 | -1.461M |
| December 31, 2011 | -0.5176M |
| September 30, 2011 | -0.0001M |
Free Cash Flow Range, Past 5 Years
-47.79M
Minimum
Sep 2023
11.15M
Maximum
Jun 2022
-19.25M
Average
-21.53M
Median
Dec 2019
Free Cash Flow Benchmarks
| Perspective Therapeutics Inc | -37.98M |
| Eli Lilly and Co | -3.152B |
| Cellectar Biosciences Inc | -33.24M |
| Outlook Therapeutics Inc | -47.10M |
| Bristol-Myers Squibb Co | 12.51B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -7.49M |
| Cash from Financing (Quarterly) | 1.192M |
| Free Cash Flow Per Share (Quarterly) | -0.2731 |
| Free Cash Flow to Equity (Quarterly) | -7.49M |
| Free Cash Flow Yield | -22.74% |